Transarterial chemoembolization refractory: current research progress
10.3969/j.issn.1008-794X.2017.12.001
- VernacularTitle:经导管动脉化疗栓塞术抵抗研究进展
- Author:
Chenxi YU
1
;
Gaojun TENG
Author Information
1. 210009,南京 东南大学医学院
- Keywords:
hepatocellular carcinoma;
transarterial chemoembolization;
refractory
- From:
Journal of Interventional Radiology
2017;26(12):1063-1067
- CountryChina
- Language:Chinese
-
Abstract:
Transarterial chemoembolization (TACE) is a standard treatment for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma (HCC),and TACE has already been widely accepted in clinical practice.Recently,more and more researches have indicated that TACE,as a palliative therapeutic regimen,carries certain defects,e.g.after several times of TACE treatment the HCC lesions become poorly-controlled.Therefore,some scholars put forward the concept of "TACE refractory".This paper aims to make a further discussion on the concept of TACE refractory and its treatment.
